Media release mylife Loop to integrate Abbott's future dual glucose-ketone sensor into its solution, combining mylife YpsoPump and mylife CamAPS FX, designed to improve the life of people living with diabetes Burgdorf, 20 June 2025, 2 p.m. – Ypsomed (SIX: YPSN) and CamDiab announce their agreement to integrate mylife Loop automated insulin delivery (AID) system with Abbott's next-generation dual glucose-ketone sensor, which is currently under development. 
The planned integration will enhance the capabilities of mylife Loop by enabling people real-time access to both glucose and ketone data through a single wearable sensor. This enhanced functionality is designed to support more informed diabetes management, particularly for people with type 1 diabetes who are at risk of diabetic ketoacidosis (DKA), a serious complication caused by elevated ketone levels in the absence of sufficient insulin. mylife Loop combines the adaptive mylife CamAPS FX app, the mylife YpsoPump insulin pump and a continuous glucose monitoring (CGM) sensor to create an interoperable AID solution designed to simplify diabetes management. "By integrating Abbott's future dual glucose-ketone sensor into mylife Loop, we aim to offer people with diabetes greater safety and confidence in their daily therapy," said Sébastien Delarive, Chief Business Officer Diabetes Care at Ypsomed. "We are excited to collaborate with Abbott on this important innovation," said Prof. Roman Hovorka, Director of CamDiab Ltd. "By incorporating future ketone monitoring alongside glucose data with the mylife CamAPS FX app, we are taking a major step forward in delivering a closed-loop solution that is designed to enhance safety and reduces burden for people – and their loved ones living with type 1 diabetes." Subject to regulatory approval, the integrated solution is expected to become available in selected markets following the commercial release of Abbott's dual glucose-ketone sensor, which is under development today. About mylife Loop mylife Loop is a modular AID solution for the treatment of type 1 diabetes. The adaptive mylife CamAPS FX algorithm runs on the personal smartphone and is approved for people with type 1 diabetes aged one year and older*, depending on the sensor used for continuous glucose monitoring. It is the only algorithm indicated for pregnant women with type 1 diabetes*. The hybrid closed-loop system mylife Loop integrates the mylife CamAPS FX app, the mylife YpsoPump insulin pump and a compatible sensor for continuous glucose monitoring, including FreeStyle Libre 3 or FreeStyle Libre 3 Plus from Abbott as well as Dexcom G6 from Dexcom. mylife Loop is marketed in most European countries, Canada, Australia and New Zealand. Further information and details can be found at http://www.mylife-diabetes-care.com/loop.
| 
